Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of RESMED INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000943819.
Disclosed value leader
VANGUARD CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- RMD on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000943819
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RESMED INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
VANGUARD CAPITAL MANAGEME...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.2%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 8.2%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
8.2%
AustralianSuper Pty Ltd
5.7%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.4%
Brett Sandercock
0.06%
Justin Leong
0.02%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
8.2%
|
$2,685,163,808
11,961,706 shares
|
$0 | 31 Mar 2026 |
| AustralianSuper Pty Ltd |
13D/G
13F
Company
|
5.7%
|
$1,725,211,619
8,276,381 shares
|
$0 | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.4%
|
$1,770,359,051
7,886,489 shares
|
$0 | 31 Mar 2026 |
| Brett Sandercock |
3/4/5
Chief Financial Officer
|
0.06%
|
$18,742,957
83,495 shares
|
-$3,599,560 | 04 May 2026 |
| Justin Leong |
3/4/5
Chief Product Officer
|
0.02%
|
$7,699,967
29,028 shares
|
— | 20 Nov 2025 |
| Ronald R. Taylor |
3/4/5
Director
|
0.02%
|
$6,570,755
24,771 shares
|
— | 20 Nov 2025 |
| Kaushik Ghoshal |
3/4/5
Chief Commercial Officer, SaaS
|
0.01%
|
$4,985,543
19,430 shares
|
— | 05 Aug 2025 |
| Carol J. Burt |
3/4/5
Director
|
0.01%
|
$4,991,131
18,816 shares
|
— | 20 Nov 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$25,943,993.
Buys
$0
Insiders: 0
Sells
$25,943,993
Insiders: 5
Net
-$25,943,993
Shares: -105,740
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 105,740
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 22,973 | $0 | $4,885,431 | -$4,885,431 |
| 3-6 | 0 | 20,973 | $0 | $4,864,671 | -$4,864,671 |
| 6-9 | 0 | 26,178 | $0 | $6,668,778 | -$6,668,778 |
| 9-12 | 0 | 35,616 | $0 | $9,525,113 | -$9,525,113 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to RESMED INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
Chairman Michael J. Farrell
Net 12M change
-$25,943,994
Latest report
07 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chairman Michael J. Farrell | Chairman and CEO, Director | $104,650,571 | -$16,856,045 | -14% | Mixed | 07 Aug 2026 |
| Robert Andrew Douglas | Special Advisor | $40,348,939 | Mixed | 02 Jan 2024 | ||
| Brett Sandercock | Chief Financial Officer | $18,742,957 | -$3,599,560 | -16% | Mixed | 04 May 2026 |
| David Pendarvis | Chief Administrative Officer | $13,694,449 | Mixed | 30 Jun 2023 | ||
| Chairman Emeritus Peter C. Farrell | Director | $12,207,367 | -$4,777,760 | -28% | Mixed | 05 Aug 2026 |
| James Hollingshead | Former President, SRC Business | $11,709,167 | Mixed | 30 Jun 2022 | ||
| Justin Leong | Chief Product Officer | $7,699,967 | Mixed | 20 Nov 2025 | ||
| Ronald R. Taylor | Director | $6,570,755 | Mixed | 20 Nov 2025 | ||
| Carol J. Burt | Director | $4,991,131 | Mixed | 20 Nov 2025 | ||
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | $4,985,543 | Mixed | 05 Aug 2025 | ||
| Richard Sulpizio | Director | $4,720,566 | Mixed | 19 Nov 2025 | ||
| Rajwant Sodhi | President, SaaS Business | $4,079,688 | Mixed | 07 Oct 2021 | ||
| Harjit Gill | Director | $2,901,944 | Mixed | 20 Nov 2025 | ||
| Karen Drexler | Director | $2,812,286 | Mixed | 20 Nov 2025 | ||
| Global Michael J. Rider | Global General Counsel | $2,129,866 | -$64,732 | -2.9% | Mixed | 01 Jun 2026 |
| RESMED INC | Director | $2,109,668 | Mixed | 18 Nov 2021 | ||
| Desney Tan | Director | $1,592,090 | Mixed | 20 Nov 2025 | ||
| Lucile Blaise | President, Sleep & RC Business | $1,572,750 | Mixed | 16 Nov 2023 | ||
| John Hernandez | Director | $1,357,600 | Mixed | 20 Nov 2025 | ||
| Jan de Witte | Director | $1,086,555 | -$645,897 | -37% | Filing P/S | 25 Nov 2025 |
Recent insider transactions for RESMED INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,026,596 | $205.69 | -4,991 | 466,256 | 07 Aug 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,247 | 07 Aug 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -25% | -4,991 | 14,975 | 07 Aug 2026 | Direct | ||
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -13.2% | $1,800,000 | $225.00 | -8,000 | 52,773 | 05 Aug 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,090,771 | $218.55 | -4,991 | 466,223 | 07 Jul 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 07 Jul 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -20% | -4,991 | 19,966 | 07 Jul 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $968,064 | $193.96 | -4,991 | 466,256 | 08 Jun 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 08 Jun 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -16.7% | -4,991 | 24,957 | 08 Jun 2026 | Direct | ||
| Global Michael J. Rider | RMD | ResMed Common Stock | Tax liability | -2.75% | -269 | 9,488 | 01 Jun 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,037,233 | $207.82 | -4,991 | 466,223 | 07 May 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 07 May 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -14.3% | -4,991 | 29,948 | 07 May 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,125,486 | $225.50 | -4,991 | 466,223 | 07 Apr 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 07 Apr 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -12.5% | -4,991 | 34,939 | 07 Apr 2026 | Direct | ||
| Brett Sandercock | RMD | ResMed Common Stock | Sale | -1.18% | $224,310 | $224.31 | -1,000 | 83,495 | 01 Apr 2026 | Direct |
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -3.19% | $450,000 | $225.00 | -2,000 | 60,773 | 01 Apr 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,252,902 | $251.03 | -4,991 | 466,223 | 09 Mar 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 09 Mar 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -11.1% | -4,991 | 39,930 | 09 Mar 2026 | Direct | ||
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -3.09% | $520,440 | $260.22 | -2,000 | 62,773 | 04 Mar 2026 | Direct |
| Brett Sandercock | RMD | ResMed Common Stock | Sale | -1.17% | $254,300 | $254.30 | -1,000 | 84,495 | 02 Mar 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,366,436 | $273.78 | -4,991 | 466,223 | 09 Feb 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 09 Feb 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -10% | -4,991 | 44,921 | 09 Feb 2026 | Direct | ||
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -3% | $502,620 | $251.31 | -2,000 | 64,773 | 04 Feb 2026 | Direct |
| Global Michael J. Rider | RMD | ResMed Common Stock | Sale | -0.51% | $13,000 | $260.00 | -50 | 9,691 | 04 Feb 2026 | Direct |
| Brett Sandercock | RMD | ResMed Common Stock | Sale | -1.16% | $257,030 | $257.03 | -1,000 | 85,495 | 02 Feb 2026 | Direct |
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -2.91% | $497,660 | $248.83 | -2,000 | 66,773 | 07 Jan 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,240,065 | $248.46 | -4,991 | 466,223 | 07 Jan 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 07 Jan 2026 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -9.09% | -4,991 | 49,912 | 07 Jan 2026 | Direct | ||
| Brett Sandercock | RMD | ResMed Common Stock | Sale | -1.14% | $241,750 | $241.75 | -1,000 | 86,495 | 02 Jan 2026 | Direct |
| Global Michael J. Rider | RMD | ResMed Common Stock | Sale | -0.51% | $12,088 | $241.75 | -50 | 9,741 | 02 Jan 2026 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Sale | -1.06% | $1,254,796 | $251.41 | -4,991 | 466,223 | 08 Dec 2025 | Direct |
| Chairman Michael J. Farrell | RMD | ResMed Common Stock | Options Exercise | 1.07% | 4,991 | 471,214 | 08 Dec 2025 | Direct | ||
| Chairman Michael J. Farrell | RMD | ResMed Common Stock Options | Options Exercise | -8.33% | -4,991 | 54,903 | 08 Dec 2025 | Direct | ||
| Chairman Emeritus Peter C. Farrell | RMD | ResMed Common Stock | Sale | -2.83% | $502,940 | $251.47 | -2,000 | 68,773 | 03 Dec 2025 | Direct |
| Global Michael J. Rider | RMD | ResMed Common Stock | Sale | -0.51% | $12,208 | $244.16 | -50 | 9,791 | 01 Dec 2025 | Direct |
| Brett Sandercock | RMD | ResMed Common Stock | Sale | -1.13% | $244,160 | $244.16 | -1,000 | 87,495 | 01 Dec 2025 | Direct |
| Jan de Witte | RMD | ReMed Common Stock | Sale | -32.5% | $524,025 | $255.00 | -2,055 | 4,261 | 25 Nov 2025 | Direct |
| Michael J. Farrell | RMD | ResMed Common Stock Options | Award | 33,288 | 33,288 | 24 Nov 2025 | Direct | |||
| Peter C. Farrell | RMD | ResMed Common Stock Options | Award | 1,331 | 1,331 | 24 Nov 2025 | Direct | |||
| Nicole Mowad-Nassar | RMD | ResMed Common Stock Options | Award | 1,331 | 1,331 | 24 Nov 2025 | Direct | |||
| Justin Leong | RMD | ReMed Common Stock | Award | 6.8% | 1,848 | 29,028 | 20 Nov 2025 | Direct | ||
| John Hernandez | RMD | ResMed Common Stock | Award | 26.5% | 1,073 | 5,118 | 20 Nov 2025 | Direct | ||
| Nicole Mowad-Nassar | RMD | ResMed Common Stock | Award | 222.4% | 536 | 777 | 20 Nov 2025 | Direct | ||
| Desney Tan | RMD | ResMed Common Stock | Award | 21.8% | 1,073 | 6,002 | 20 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.